Comparison of Mutations and Protein Expression in Potentially Actionable Targets in 5,500 Triple Negative vs. Non-Triple Negative Breast Cancers


Joyce A O’Shaughnessy, Zoran Gatalica, Jeffery Kimbrough, Sherri Z Millis


Triple negative breast cancer is a heterogeneous disease with no established targeted treatment options for patients with metastatic disease. This study was undertaken to profile a large commercial biomarker database in an effort to identify potential molecular differences between triple negative and non-triple negative breast cancers and to identify potential new molecular therapeutic targets.

Download Publication